FAP+ stromal cells have been shown to suppress anti-tumor immunity [153], and CXCL12 produced by FAP+ CAFs drives T cell exclusion and blunts responses to αCTLA-4/αPD-L1, findings that motivated later CXCR4-blockade combinations [154]. The gene discussed is FAP; the disease is neoplasm.